Trade Summary

2 days ago, Schilke Tobin, serving as CFO at Crinetics Pharmaceuticals, Inc. (CRNX), sold 6,713 shares at $39.67 per share, for a total transaction value of $266,305.00. Following this transaction, Schilke Tobin now holds 78,121 shares of CRNX.

This sale represents a 8.00% decrease in Schilke Tobin's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, March 3, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, March 4, 2026, 1 day after the trade was made.

Crinetics Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.